Laura Goff, MD
Hematology & Oncology · Nashville, TNNPI 1023165909
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,085 of the $22,114 with a category attached, or 63.7%. 9 manufacturers reported payments, led by Merck at 34.4% of the total. Reporting peaked in 2024 at $10,666 and has fallen 82.0% since, to $1,920 in 2025.
Across 19 payments — averaging $1163.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8K
- E.r. Squibb & Sons, L.L.C.$5K
- AstraZeneca$4K
- Genentech USA, Inc.$2K
- Exelixis Inc.$2K
- Boehringer Ingelheim International GmbH$2K
- plus $260 from 3 others
Across 111 payments — averaging $7173.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$420K
- E.r. Squibb & Sons, L.L.C.$202K
- Agios Pharmaceuticals, Inc.$94K
- Beigene, Ltd.$61K
- Eli Lilly$11K
- Incyte Corporation$7K
- plus $1K from 1 others
What the payments were for
- Consulting fees$14,08564%
- Speaking & faculty fees$7,75035%
- Food & beverage$2791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $7,600 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,800 |
| AstraZeneca | 3 | $4,399 |
| Genentech USA, Inc. | 1 | $1,830 |
| Exelixis Inc. | 1 | $1,650 |
| Boehringer Ingelheim International GmbH | 2 | $1,575 |
| GSK | 6 | $158 |
| Array Biopharma Inc | 1 | $55 |
| Jazz Pharmaceuticals Inc. | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,114 in reported general payments places this provider in the 75th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $9,904 |
| Ondansetron Hcl | 19 | $2,297 |
| Oxycodone Hcl | 14 | $448 |
| Gabapentin | 13 | $230 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.